Upstream Biosciences Begins Animal Efficacy Testing For Trypanosomiasis Treatment

Company reaches a significant development milestone in program to treat Trypanosomiasis

Vancouver, British Columbia CANADA, September 15, 2008 /FSC/ - Upstream Biosciences Inc.  (UPBS - OTCBB), announced today that it has begun animal efficacy testing in collaboration with Makerere University in Kampala, Uganda to evaluate its proprietary drug candidates as potential livestock and human treatments for Trypanosomiasis. Management anticipates that this research will lead to the selection of a drug candidate to treat Trypanosomiasis initially in livestock followed by a human treatment for the disease.

"We are excited that our R&D programs have yielded several high quality preclinical candidates for the treatment of Trypanosomiasis," said Bellenson. "The results of this round of testing are expected to allow us to take an important step towards developing our first drug for a veterinary application in Africa. Our treatment for this devastating disease could have a huge economic impact on Africa. Trypanosomiasis causes an estimated annual economic loss of US$4.5 billion and impacts a geographic area the size of Canada."

Upstream has demonstrated in vitro efficacy and in vivo (in animals) safety for potential treatments for Trypanosomiasis, Leishmaniasis, and Malaria. Trypanosomiasis, Leishmaniasis, and Malaria are caused by related parasites that have developed resistance to available treatments. An estimated 60 million people and 50 million cattle and other animals in sub-Saharan Africa are at risk of contracting Trypanosomiasis. Drug resistance has greatly reduced the effectiveness of existing Trypanosomiasis treatments. Leishmaniasis afflicts millions of people living in Africa, India, and the Middle East. According to the World Health Organization, about 40% of the world's population is at risk of Malaria. These diseases will be included in the United States Food and Drug Administration's proposed priority review voucher program designed to provide financial incentive to companies developing treatments.

The Trypanosomiasis testing will be conducted at Makerere University Faculty of Veterinary Medicine, Dept. of Parasitology and Microbiology, in Kampala, Uganda. Testing will directed by Prof. George Lubega, department head, and by Dr. Enock Matovu.

"We are very pleased to play an important role in Upstream's rapidly-advancing program to develop a treatment for Trypanosomiasis," said Prof. Lubega. "An effective treatment for Trypanosomiasis in livestock could significantly increase the production of dairy, meat, and agricultural products across sub-Saharan Africa."

About Makerere University

Makerere University located in Kampala, Uganda is one of sub-Saharan Africa's oldest and most prestigious institutions of higher learning.